The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1330
Ustekinumab (Stelara) for Psoriasis
The full article is available to subscribers Subscriber Login   
Revised 3/4/10: Footnote 2 in table 2 should have included a second sentence: $5595.60 is the cost of one 45-mg syringe.

The FDA has approved the use of ustekinumab (Stelara – Centocor Ortho Biotech), an interleukin antagonist given by subcutaneous (SC) injection for treatment of adults with moderate to severe plaque psoriasis. It is the first agent in its class for this indication; the other biologic agents for psoriasis are Tcell or tumor necrosis factor (TNF) inhibitors.1

MECHANISM OF ACTION — Ustekinumab is a fully human IgG1 antibody directed against the p40 subunit of IL-12 and IL-23 cytokines, which are present in psoriasis skin lesions. These cytokines activate inflammatory and immune responses thought to be involved in the keratinocyte hyperplasia characteristic of psoriasis.

DRUGS FOR PSORIASIS — Mild to moderate psoriasis is generally treated with topical corticosteroids; calcitriol (Vectical), calcipotriene (Dovonex, and others) or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Ustekinumab (Stelara) for Psoriasis
Article code: 1330c
 Electronic, downloadable article - $25